Voyager Therapeutics Inc.
VYGR | NASDAQ
$3.08
-$0.01 (-0.32%)
At close: Sep 21, 2026, 4:00 PM ET
$3.09
+$0.01 (+0.32%)
Pre-market:
Sep 22, 2026, 7:00 AM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 40.37M | 80M | 250.01M | 40.91M | 37.42M | 171.13M |
Cost of Revenue | 132.27M | n/a | 92.17M | 55.76M | 73.79M | 108.75M |
Gross Profit | -91.9M | 80M | 157.84M | -14.86M | -36.37M | 62.38M |
Operating Income | -131.84M | -83.29M | 122.01M | -50.84M | -73.62M | 27.38M |
Interest Income | 10.62M | 18.33M | 11.72M | 1.79M | n/a | 1.66M |
Pretax Income | -119.58M | -64.34M | 133.74M | -46.39M | -71.2M | 36.74M |
Net Income | -119.72M | -65M | 132.33M | -46.41M | -71.2M | 36.74M |
Selling & General & Admin | 36.44M | 35.92M | 35.82M | 30.98M | 37.25M | 34.99M |
Research & Development | 134.67M | 127.37M | 92.17M | 60.76M | 73.79M | 108.75M |
Other Expenses | -131.17M | n/a | -92.17M | -55.76M | -73.79M | -108.75M |
Operating Expenses | 39.94M | 163.29M | 35.82M | 35.98M | 37.25M | 34.99M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 172.22M | 163.29M | 127.99M | 91.74M | 111.03M | 143.74M |
Income Tax Expense | 144K | 665K | 1.41M | 16K | n/a | n/a |
Shares Outstanding (Basic) | 58.69M | 57.67M | 43.02M | 38.36M | 37.67M | 37.13M |
Shares Outstanding (Diluted) | 58.69M | 57.67M | 44.57M | 38.36M | 37.67M | 37.35M |
EPS (Basic) | -2.04 | -1.13 | 3.08 | -1.21 | -1.75 | 0.99 |
EPS (Diluted) | -2.04 | -1.13 | 2.97 | -1.21 | -1.75 | 0.98 |
EBITDA | -115.52M | -59.61M | 138.18M | -39.65M | -66.03M | 31.2M |
EBIT | -119.58M | -64.34M | 133.74M | -45.84M | -71.2M | 27.38M |
Depreciation & Amortization | 4.06M | 4.73M | 4.44M | 6.19M | 5.17M | 3.82M |
Add to Watchlist
Select watchlists to add or remove VYGR